Literature DB >> 6498130

Invasive cervical cancer in young women.

C la Vecchia, S Franceschi, A Decarli, G Gallus, F Parazzini, E Merlo.   

Abstract

Between 1970 and 1979, 103 women below 35 years of age with invasive cervical cancer were treated at the First Obstetrics and Gynaecology Clinic of the University of Milan. Nine patients were pregnant or less than 3 months postpartum. Estimated 10-year disease-free survival, determined by the life-table method, was 100% in stage IA (37 patients), 79% in stage IB (45 patients), 67% in stage II (15 patients), 0% in stages III (5 patients) and IV (1 patient). Prognosis was also strongly associated with lymph-node involvement, 10-year actuarial survival decreasing from 93% in lymph-node-negative to 44% in lymph-node-positive patients (P less than 0.001). The prognostic relevance of the clinical stage decreased after adjustment for lymph-node involvement, but the statistical significance of lymph-node involvement was unaffected when stage was allowed for. In the present series, the estimated 10-year disease-free survival was 80% in patients treated by radical hysterectomy compared with 62% in the group treated by total hysterectomy (stage IB to IV patients only); this difference, however, was not statistically significant when the data were adjusted for clinical stage (P = 0.10). None of the 20 patients with recurrent disease could be managed successfully.

Entities:  

Mesh:

Year:  1984        PMID: 6498130     DOI: 10.1111/j.1471-0528.1984.tb15093.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  2 in total

1.  Changing character of cervical cancer in young women.

Authors:  P M Elliott; M H Tattersall; M Coppleson; P Russell; F Wong; A S Coates; H J Solomon; P M Bannatyne; K H Atkinson; J C Murray
Journal:  BMJ       Date:  1989-02-04

2.  Using decision analysis to calculate the optimum treatment for microinvasive cervical cancer.

Authors:  N Johnson; R J Lilford; S E Jones; L McKenzie; P Billingsley; F F Songane
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.